ONXEO
Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma. Onxeo is headquartered in Paris, France.
ONXEO
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
1997-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.onxeo.com
Total Employee:
11+
Status:
Active
Contact:
+330145587600
Total Funding:
60.4 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Alix
Alix SA is a biotechnology company that develops drugs for the identification of therapeutic targets.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Prestizia
Prestizia is a biotechnology company that is developing a microRNA1 technology.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-02-29 | DNA Therapeutics | DNA Therapeutics acquired by Onxeo | 1.85 M USD |
| 2007-06-27 | TopoTarget Switzerland | TopoTarget Switzerland acquired by Onxeo | N/A |
| 2002-06-04 | TopoTarget UK Limited | TopoTarget UK Limited acquired by Onxeo | N/A |
Investors List
Invus
Invus investment in Post-IPO Equity - Onxeo
Financière de la Montagne
Financière de la Montagne investment in Post-IPO Equity - Onxeo
Bpifrance
Bpifrance investment in Post-IPO Equity - Onxeo
Oséo
Oséo investment in Grant - Onxeo
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-07 | Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer |
| 2022-01-03 | Onxeo Appoints Julien Miara as New Interim CEO |
Official Site Inspections
http://www.onxeo.com Semrush global rank: 5.13 M Semrush visits lastest month: 1.59 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Onxeo"
Onxeo - Crunchbase Company Profile & Funding
Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell …See details»
Valerio Therapeutics: Transforming Cancer & Inflammatory …
Valerio Therapeutics is a clinical-stage biotechnology company leading the way in the development of innovative DNA decoy therapeutics. Focusing exclusively on intracellular DNA …See details»
Onxeo changes its name and becomes Valerio Therapeutics …
Paris (France), June 6, 2023 – 6:30 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the …See details»
News and Media - Valerio Therapeutics
Apr 30, 2024 Onxeo changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023 (English) All the resolutions approved by the …See details»
Press Release Distribution and Management - GlobeNewswire
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitorsIntroducing OX400, a new generation of PARP interfering cancer drug candidates PARIS, April 08, 2021 (GLOBE …See details»
Onxeo : changes its name and becomes Valerio Therapeutics …
Jun 6, 2023 All the resolutions approved by the Board of Directors were adopted Paris , June 6, 2023 - 6:30 pm CEST - Onxeo S.A. , , a clinical-stage biotechnology company specializing in...See details»
Valerio Therapeutics (ex-Onxeo) - Boursier.com
Consultez le profil de la société Valerio Therapeutics (ex-Onxeo). Accédez au descriptif des secteurs d'activité, à la liste des dirigeants et des actionnaires ainsi qu'aux caractéristiques ...See details»
Valerio Therapeutics Société anonyme Stock (ONXEO) - Quote …
Oct 24, 2001 Valerio Therapeutics (formerly Onxeo) is a clinical-stage biotechnology company developing novel cancer drugs by targeting tumor DNA functions through unparalleled …See details»
Dr. Shefali Agarwal - Fate Therapeutics
Dr. Shefali Agarwal formerly served as President, Chief Executive Officer, and Chair of the Board of Onxeo S.A., a clinical stage biotechnology company developing drugs targeting DNA …See details»
Cours action Valerio Therapeutics (ex-Onxeo), cotation Bourse en …
Consultez le cours de l'action Valerio Therapeutics (ex-Onxeo) en direct (intraday). Accédez aux dernières transactions de l'action ALVIO - FR0010095596, au carnet d'ordre, comparez …See details»
DARA BioSciences Announces the Acquisition of Exclusive North …
Mar 10, 2015 Additionally DARA's field sales organization is contracted through Alamo Pharma services, a subsidiary of Mission Pharmacal. ... Onxeo has the vision to become a global …See details»
Onxeo Reports its Half-Year 2022 Financial Results and Provides an ...
Sep 13, 2022 Dr. Shefali Agarwal, President and CEO of Onxeo, said: "This first half of the year has been an opportunity for Onxeo to undergo profound transformations, both in its …See details»
Onxeo Appoints Dr. Shefali Agarwal as President and Chief …
Apr 7, 2022 She is also on the Scientific Advisory Board of Imvax, Inc. and is the Founder of Cancer Shakti Foundation, a voluntary non-profit organization dedicated to raising cancer …See details»
Onxeo Further strengthens its Board of Directors with two
Oct 14, 2021 Onxeo Valerie Leroy, Investor Relations [email protected] +33 1 45 58 76 00: Media Relations Nicolas Merigeau NewCap [email protected] +33 1 44 71 94 98See details»
Onxeo Enters Clinical Research Agreement with Gustave
Jan 29, 2020 Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding …See details»
VIO-01 / Valerio Therap - LARVOL
ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNA (Businesswire) - "'Additionally, this lays a strong foundation for our next first in class …See details»
Onxeo to Attend Key Investor and Scientific Conferences
Jan 11, 2021 Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding …See details»
Onxeo en bourse : quels sont les enjeux pour les investisseurs
Dec 16, 2024 Positionnement d’Onxeo dans le secteur biopharmaceutique. La société Onxeo se distingue sur le marché avec une expertise dans le domaine biopharmaceutique, spécialisée …See details»
Onxeo to study prostate cancer drug - Labiotech.eu
Jan 27, 2023 Onxeo’s AsiDNA is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist …See details»
OXNXF: Dividend Date & History for Onxeo SA - Dividend.com
Onxeo SA Payout Change Inactive Price as of: JUL 28, 07:59 PM EDT Not trading Dividend (Fwd) $0.00 Yield (Fwd) Annualized forward dividend yield. Multiplies the most recent dividend …See details»